Today: 28 June 2026
Browse Category

NASDAQ:REVB 23 January 2026

Revelation Biosciences (REVB) stock ticks up premarket after FDA lays out Gemini trial path

Revelation Biosciences (REVB) stock ticks up premarket after FDA lays out Gemini trial path

Revelation Biosciences shares rose about 2% premarket after an SEC filing showed FDA agreement on a single adaptive Phase 2/3 trial for its Gemini program in acute kidney injury. The company said strong results from roughly 300 patients could support a U.S. approval filing. Shares last traded near $0.85. Investors remain focused on trial timing and the firm’s $12.7 million cash position.
23 January 2026
··

Stock Market Today

  • XRP Tests $1 Level Amid Fed Inflation Concerns: 3 Market Scenarios
    June 28, 2026, 3:22 AM EDT. XRP's price hit a low of $1.00 following the Federal Reserve's inflation data, reflecting heightened market caution. The personal consumption expenditures price index, the Fed's preferred inflation measure, rose to its highest since 2023, intensifying uncertainty. XRP dipped after three consecutive days of selling, briefly breaking a key support level at $1.06 where large volume traded. Bulls reclaimed ground, pushing XRP up 2.95% to $1.07. Analysts now consider three potential scenarios for XRP's near-term price action. The digital asset's performance remains tied to broader economic signals and investor sentiment toward Federal Reserve policies.

Latest articles

Hecla Mining (NYSE:HL) sees stock rebound, volume jumps as silver prices in focus

Hecla Mining (NYSE:HL) sees stock rebound, volume jumps as silver prices in focus

28 June 2026
Hecla Mining surged 5.3 times its average trading volume Friday as index rebalancing drove 112.44 million shares traded, but the stock’s 2.6% weekly drop still beat silver and peer ETFs, signaling company-specific strength; investors now watch if Hecla can hold above $15.54 without rebalancing flows as macro risks loom.
Go toTop